3 ms·

What I do not understand from a market perspective is why insurers don't cooperate more to fund such research. If a treatment goes from 20k to 1k p.a. the benef

by wjnc 9y ago

What I do not understand from a market perspective is why insurers don't cooperate more to fund such research. If a treatment goes from 20k to 1k p.a. the benefits for insurers are clear. They could even fund such research in an equity-fashion, that way steering clear of anti-competition law and free-rider problems (just sell it to the non-cooperators for 20k).

ergothus 9y ago
That is an incentive to insurers only if they are paying the price or if the lower costs to a specific group of consumers increases their market share. Since most costs are passed on to the consumers and most consumers don't get to pick their insurance (in the U.S.) , the incentives aren't there.
- DenisM 9y ago
  Employers do pick insurance companies, and cost is a big factor.
  - ergothus 9y ago
    But if the cost is passed on to employees, that cost does not impact the employers. If said cost applies to only some of the employees, the employer won't have much in the way of even indirect incentives.